CST-103 Improves Brain Blood Flow in Early Clinical Trial

CST-103 Improves Brain Blood Flow in Early Clinical Trial

311591

CST-103 Improves Brain Blood Flow in Early Clinical Trial

Treatment with the investigational therapy CST-103 increased blood flow to certain regions of the brains of people with Parkinson’s disease and mild cognitive impairment, results of a small clinical trial show. The type of increased blood flow that was seen “correlates with increased neuronal activity and cognitive benefit,” Gabriel Vargas, MD, PhD, said in a press release. Vargas is chief medical officer of CuraSen Therapeutics, which is developing CST-103. According to CuraSen, people with Parkinson’s…

You must be logged in to read/download the full post.